170 related articles for article (PubMed ID: 34783452)
1. Phase 1 Maximal Use Pharmacokinetic Study of Tirbanibulin Ointment 1% in Subjects With Actinic Keratosis.
Yavel R; Overcash JS; Cutler D; Fang J; Zhi J
Clin Pharmacol Drug Dev; 2022 Mar; 11(3):397-405. PubMed ID: 34783452
[TBL] [Abstract][Full Text] [Related]
2. Tirbanibulin Ointment 1% as a Novel Treatment for Actinic Keratosis: Phase 1 and 2 Results.
Kempers S; DuBois J; Forman S; Poon A; Cutler E; Wang H; Cutler D; Fang J; Kwan R
J Drugs Dermatol; 2020 Nov; 19(11):1093-1100. PubMed ID: 33196758
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, Safety, and Tolerability of a Single 5-Day Treatment of Tirbanibulin Ointment 1% in 100 cm
DuBois J; Jones TM; Lee MS; Falqués M; Kiyasova V; Jiménez G; Otero R; Jansat JM; Aubets J; Forconi RJ
Clin Pharmacol Drug Dev; 2024 Feb; 13(2):208-218. PubMed ID: 38185925
[TBL] [Abstract][Full Text] [Related]
4. Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
Blauvelt A; Kempers S; Lain E; Schlesinger T; Tyring S; Forman S; Ablon G; Martin G; Wang H; Cutler DL; Fang J; Kwan MR;
N Engl J Med; 2021 Feb; 384(6):512-520. PubMed ID: 33567191
[TBL] [Abstract][Full Text] [Related]
5. Tirbanibulin 1% Ointment for Actinic Keratosis: Results from a Real-Life Study.
Li Pomi F; Vaccaro M; Pallio G; Rottura M; Irrera N; Borgia F
Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399512
[No Abstract] [Full Text] [Related]
6. 1% Tirbanibulin Ointment for the Treatment of Actinic Keratoses.
Dao DD; Sahni VN; Sahni DR; Balogh EA; Grada A; Feldman SR
Ann Pharmacother; 2022 Apr; 56(4):494-500. PubMed ID: 34301153
[TBL] [Abstract][Full Text] [Related]
7. Tirbanibulin: Topical Treatment for Actinic Keratosis.
Dlott AH; Di Pasqua AJ; Spencer SA
Clin Drug Investig; 2021 Sep; 41(9):751-755. PubMed ID: 34351607
[TBL] [Abstract][Full Text] [Related]
8. Tirbanibulin for the Treatment of Actinic Keratosis: A Review.
Miller AC; Adjei S; Temiz LA; Tyring SK
Skin Therapy Lett; 2022 Jul; 27(4):4-7. PubMed ID: 35857917
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of tirbanibulin 1% ointment in actinic keratoses: Data from two phase-III trials and the real-life clinical practice presented at the European Academy of Dermatology and Venereology Congress 2022.
Pellacani G; Schlesinger T; Bhatia N; Berman B; Lebwohl M; Cohen JL; Patel GK; Kunstfeld R; Hadshiew I; Lear JT
J Eur Acad Dermatol Venereol; 2024 Jan; 38 Suppl 1():3-15. PubMed ID: 38116638
[TBL] [Abstract][Full Text] [Related]
10. Tirbanibulin 1% ointment (Klisyri) for actinic keratosis.
Med Lett Drugs Ther; 2021 May; 63(1623):70-71. PubMed ID: 33976100
[No Abstract] [Full Text] [Related]
11. Tirbanibulin 1% Ointment Significantly Reduces the Actinic Keratosis Area and Severity Index in Patients with Actinic Keratosis: Results from a Real-World Study.
Kirchberger MC; Gfesser M; Erdmann M; Schliep S; Berking C; Heppt MV
J Clin Med; 2023 Jul; 12(14):. PubMed ID: 37510952
[TBL] [Abstract][Full Text] [Related]
12. Profile of Tirbanibulin for the Treatment of Actinic Keratosis.
Berman B; Grada A; Berman DK
J Clin Aesthet Dermatol; 2022 Oct; 15(10 Suppl 1):S3-S10. PubMed ID: 36408375
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor effects of tirbanibulin in squamous cell carcinoma cells are mediated via disruption of tubulin-polymerization.
DeTemple VK; Walter A; Bredemeier S; Gutzmer R; Schaper-Gerhardt K
Arch Dermatol Res; 2024 Jun; 316(7):341. PubMed ID: 38847867
[TBL] [Abstract][Full Text] [Related]
14. Tirbanibulin for Actinic Keratosis: Insights into the Mechanism of Action.
Schlesinger T; Stockfleth E; Grada A; Berman B
Clin Cosmet Investig Dermatol; 2022; 15():2495-2506. PubMed ID: 36415541
[TBL] [Abstract][Full Text] [Related]
15. Focused update: Guidelines of care for the management of actinic keratosis.
Eisen DB; Dellavalle RP; Frazer-Green L; Schlesinger TE; Shive M; Wu PA
J Am Acad Dermatol; 2022 Aug; 87(2):373-374.e5. PubMed ID: 35439607
[TBL] [Abstract][Full Text] [Related]
16. Patient- and Clinician-Reported Outcomes for Tirbanibulin in Actinic Keratosis in Clinical Practice Across the United States (PROAK).
Schlesinger T; Kircik L; Lebwohl M; Patel VA; Berman B; Bhatia N; Rigel D; Armstrong A; Rosso JD; Narayanan S; Koscielny V
J Drugs Dermatol; 2024 May; 23(5):338-346. PubMed ID: 38709702
[TBL] [Abstract][Full Text] [Related]
17. Contact Sensitization and Phototoxic and Photoallergic Potential of Tirbanibulin 1% Ointment in Healthy Volunteers.
Dosik J; Cutler DL; Fang J; Padullés L
JID Innov; 2023 Mar; 3(2):100170. PubMed ID: 36699198
[TBL] [Abstract][Full Text] [Related]
18. Preliminary Evidence of Efficacy, Safety, and Treatment Satisfaction with Tirbanibulin 1% Ointment: A Clinical Perspective on Actinic Keratoses.
Campione E; Rivieccio A; Gaeta Shumak R; Costanza G; Cosio T; Lambiase S; Garofalo V; Artosi F; Lozzi F; Freni C; Romeo A; Dika E; Falconi M; Bianchi L
Pharmaceuticals (Basel); 2023 Dec; 16(12):. PubMed ID: 38139813
[TBL] [Abstract][Full Text] [Related]
19. Tirbanibulin (Klisyri) for the Treatment of Actinic Keratosis.
Geer K
Am Fam Physician; 2021 Nov; 104(5):519-520. PubMed ID: 34783508
[No Abstract] [Full Text] [Related]
20. Pharmacokinetics and Safety of Ingenol Disoxate Gel Administered Under Maximum-Use Conditions to Patients With Actinic Keratosis.
Lain E; Skov T; Hall A
Clin Drug Investig; 2018 Mar; 38(3):249-257. PubMed ID: 29204958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
